Literature DB >> 2014634

Immunodominance and antigenic variation of the principal neutralization domain of HIV-1.

G Zwart1, H Langedijk, L van der Hoek, J J de Jong, T F Wolfs, C Ramautarsing, M Bakker, A de Ronde, J Goudsmit.   

Abstract

The principal neutralization domain (PND) of HIV-1 is located in the third variable region (V3) of the envelope glycoprotein gp 120. Cross-reactivity of experimental and natural sera with recombinant proteins containing the V3 region of four HIV-1 variants showed that a group of viruses (among which HIV-1 MN) had antigenically similar V3 regions. The V3 regions of HIV-1 IIIB and HIV-1 RF were antigenically distinct. Antibodies raised to V3 domains of two isolates from the "MN group" neutralized HIV-1 MN (and not HIV-1 IIIB), thus confirming the antigenic similarity of V3 of these isolates to that of HIV-1 MN. Human antibodies to the V3 region were shown to be mainly directed to the central area in V3, where the neutralization domain is. In addition, antibody reactivities in sera of 397 Dutch and 39 Tanzanian HIV-1-infected individuals show that the V3 neutralization domain is highly antigenic, and that viruses from the MN group predominate in The Netherlands and to a lesser extent in Tanzania. Thus, if the protective value of antibodies to the PND can be established, then PND (poly)peptides derived from the MN group may be important components of a subunit vaccine against HIV-1.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2014634     DOI: 10.1016/0042-6822(91)90880-k

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  38 in total

1.  Effect of soluble CD4 on exposure of epitopes on primary, intact, native human immunodeficiency virus type 1 virions of different genetic clades.

Authors:  H A Mbah; S Burda; M K Gorny; C Williams; K Revesz; S Zolla-Pazner; P N Nyambi
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

Review 2.  Cellular and humoral antigenic epitopes in HIV and SIV.

Authors:  D F Nixon; K Broliden; G Ogg; P A Broliden
Journal:  Immunology       Date:  1992-08       Impact factor: 7.397

3.  Examination of sera from human immunodeficiency virus type 1 (HIV-1)-infected individuals for antibodies reactive with peptides corresponding to the principal neutralizing determinant of HIV-1 gp120 and for in vitro neutralizing activity.

Authors:  R Q Warren; S A Anderson; W M Nkya; J F Shao; C W Hendrix; G P Melcher; R R Redfield; R C Kennedy
Journal:  J Virol       Date:  1992-09       Impact factor: 5.103

4.  Conserved structural elements in the V3 crown of HIV-1 gp120.

Authors:  Xunqing Jiang; Valicia Burke; Maxim Totrov; Constance Williams; Timothy Cardozo; Miroslaw K Gorny; Susan Zolla-Pazner; Xiang-Peng Kong
Journal:  Nat Struct Mol Biol       Date:  2010-07-11       Impact factor: 15.369

5.  Characterization of antibody responses elicited by human immunodeficiency virus type 1 primary isolate trimeric and monomeric envelope glycoproteins in selected adjuvants.

Authors:  Y Li; K Svehla; N L Mathy; G Voss; J R Mascola; R Wyatt
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

6.  Patterns of HIV-1 evolution in individuals with differing rates of CD4 T cell decline.

Authors:  R B Markham; W C Wang; A E Weisstein; Z Wang; A Munoz; A Templeton; J Margolick; D Vlahov; T Quinn; H Farzadegan; X F Yu
Journal:  Proc Natl Acad Sci U S A       Date:  1998-10-13       Impact factor: 11.205

7.  Mutations in both gp120 and gp41 are responsible for the broad neutralization resistance of variant human immunodeficiency virus type 1 MN to antibodies directed at V3 and non-V3 epitopes.

Authors:  E J Park; L K Vujcic; R Anand; T S Theodore; G V Quinnan
Journal:  J Virol       Date:  1998-09       Impact factor: 5.103

8.  Location, exposure, and conservation of neutralizing and nonneutralizing epitopes on human immunodeficiency virus type 2 SU glycoprotein.

Authors:  A McKnight; C Shotton; J Cordell; I Jones; G Simmons; P R Clapham
Journal:  J Virol       Date:  1996-07       Impact factor: 5.103

9.  Microarray profiling of antibody responses against simian-human immunodeficiency virus: postchallenge convergence of reactivities independent of host histocompatibility type and vaccine regimen.

Authors:  Henry E Neuman de Vegvar; Rama Rao Amara; Lawrence Steinman; Paul J Utz; Harriet L Robinson; William H Robinson
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

10.  Selection for specific sequences in the external envelope protein of human immunodeficiency virus type 1 upon primary infection.

Authors:  L Q Zhang; P MacKenzie; A Cleland; E C Holmes; A J Brown; P Simmonds
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.